CR20230172A - Péptidos amidados y sus contrapartes desamidadas representadas mediante hla-a*02 para su uso en inmunoterapia contra diferentes tipos de cánceres. - Google Patents

Péptidos amidados y sus contrapartes desamidadas representadas mediante hla-a*02 para su uso en inmunoterapia contra diferentes tipos de cánceres.

Info

Publication number
CR20230172A
CR20230172A CR20230172A CR20230172A CR20230172A CR 20230172 A CR20230172 A CR 20230172A CR 20230172 A CR20230172 A CR 20230172A CR 20230172 A CR20230172 A CR 20230172A CR 20230172 A CR20230172 A CR 20230172A
Authority
CR
Costa Rica
Prior art keywords
hla
cancers
different types
against different
immunotherapy against
Prior art date
Application number
CR20230172A
Other languages
English (en)
Inventor
Jens Hukelmann
Franziska Hoffgaard
Ricarda Hannen
Daniel Kowalewski
Oliver Schoor
Heiko Schuster
Jens Fritsche
Christoph Schräder
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CR20230172A publication Critical patent/CR20230172A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

La invención se refiere a un péptido que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en (I) la SEQ ID n.º: 1 a la SEQ ID n.º: 102, y (II) una secuencia variante de la misma que mantiene la capacidad de unirse a las moléculas del MHC y/o inducir la reacción cruzada de las células T con dicho péptido variante, o una sal farmacéuticamente aceptable de este.
CR20230172A 2020-09-29 2021-09-29 Péptidos amidados y sus contrapartes desamidadas representadas mediante hla-a*02 para su uso en inmunoterapia contra diferentes tipos de cánceres. CR20230172A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084963P 2020-09-29 2020-09-29
DE102020125457.1A DE102020125457A1 (de) 2020-09-29 2020-09-29 Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
PCT/EP2021/076821 WO2022069557A2 (en) 2020-09-29 2021-09-29 Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancers

Publications (1)

Publication Number Publication Date
CR20230172A true CR20230172A (es) 2023-06-23

Family

ID=80624439

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230172A CR20230172A (es) 2020-09-29 2021-09-29 Péptidos amidados y sus contrapartes desamidadas representadas mediante hla-a*02 para su uso en inmunoterapia contra diferentes tipos de cánceres.

Country Status (14)

Country Link
US (14) US11833195B2 (es)
EP (1) EP4221743A2 (es)
JP (1) JP2023542997A (es)
KR (1) KR20230079160A (es)
CN (1) CN116997355A (es)
AR (1) AR123634A1 (es)
AU (1) AU2021353977A1 (es)
BR (1) BR112023005798A2 (es)
CA (1) CA3193564A1 (es)
CR (1) CR20230172A (es)
DE (1) DE102020125457A1 (es)
MX (1) MX2023003367A (es)
TW (1) TW202229311A (es)
WO (1) WO2022069557A2 (es)

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
JP2530801B2 (ja) 1978-12-22 1996-09-04 バイオゲン インコーポレイテッド 組換えｄｎａ分子
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
GB2294267B (en) 1993-06-03 1996-11-20 Therapeutic Antibodies Inc Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
CA2569240A1 (en) 2004-06-01 2005-12-15 Domantis Limited Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
SI2113253T1 (sl) 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US20140170168A1 (en) 2010-10-26 2014-06-19 Yoram Reiter Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
WO2020072700A1 (en) * 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines

Also Published As

Publication number Publication date
MX2023003367A (es) 2023-06-14
US11904003B2 (en) 2024-02-20
US20240024440A1 (en) 2024-01-25
US20240016910A1 (en) 2024-01-18
BR112023005798A2 (pt) 2023-04-25
KR20230079160A (ko) 2023-06-05
US20240016911A1 (en) 2024-01-18
US20240016913A1 (en) 2024-01-18
TW202229311A (zh) 2022-08-01
WO2022069557A3 (en) 2022-05-12
US20220111022A1 (en) 2022-04-14
AR123634A1 (es) 2022-12-28
CA3193564A1 (en) 2022-04-07
US20240016912A1 (en) 2024-01-18
AU2021353977A1 (en) 2023-05-04
US11833195B2 (en) 2023-12-05
US20240075119A1 (en) 2024-03-07
US20240016909A1 (en) 2024-01-18
WO2022069557A2 (en) 2022-04-07
US20230338488A1 (en) 2023-10-26
US20240016906A1 (en) 2024-01-18
US20240024441A1 (en) 2024-01-25
CN116997355A (zh) 2023-11-03
US20230414734A1 (en) 2023-12-28
DE102020125457A1 (de) 2022-03-31
US20230285525A1 (en) 2023-09-14
US20240075118A1 (en) 2024-03-07
EP4221743A2 (en) 2023-08-09
JP2023542997A (ja) 2023-10-12
US20240016907A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
AR106920A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
NZ708990A (en) Method for activating helper t cell
RU2009128979A (ru) Hla*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция
EP2573109A3 (en) Peptide vaccines comprising Seq Id 101, 80 or 100 for cancers expressing tumor-associated antigens
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
JP2017522362A5 (es)
RU2013112616A (ru) Пептид cdca1 и включающее его фармацевтическое средство
RU2009141595A (ru) Пептиды тем8 и содержащие их вакцины
MX2022005922A (es) Receptores de tcr de prame y usos de estos.
RU2012127358A (ru) Олигопептиды imp-3 и содержащие их вакцины
NZ705899A (en) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
RU2011138160A (ru) Пептиды foxmi и вакцины, содержащие их
JP2019527066A5 (es)
RU2015143164A (ru) Пептиды kntc2 и содержащие их вакцины
RU2009129531A (ru) Вакцины на основе пептида foxp3
RU2012136464A (ru) Модифицированные пептиды melk и содержащие их вакцины
JP2015529219A5 (es)
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
CR20230172A (es) Péptidos amidados y sus contrapartes desamidadas representadas mediante hla-a*02 para su uso en inmunoterapia contra diferentes tipos de cánceres.
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
EP1842911A4 (en) HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS
WO2022069579A3 (en) Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers
MX2010005816A (es) Epítopos de péptido de stat3.